Weight Loss Drugs Market, By Type (Over-the-counter drugs (OTC) and Prescription Drugs), By Dosage Form, By Application, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4161
|
Published Date
July 2025
|
Pages
303
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Weight Loss Drugs Market size was valued at US$ 54,503.22 Million in 2024, expanding at a CAGR of 19.29% from 2025 to 2032.
The Weight Loss Drugs Market is a global industry focused on the development, manufacturing, and commercialization of pharmaceutical products designed to support weight reduction and obesity management. These drugs work through various mechanisms, including appetite suppression, inhibition of fat absorption, and metabolic enhancement, helping individuals manage overweight and obesity-related conditions.
The market encompasses a wide range of offerings, including prescription medications, over-the-counter (OTC) products, and emerging therapies targeting the growing prevalence of obesity worldwide. Rising awareness of the health risks linked to obesity—such as diabetes, cardiovascular diseases, and certain cancers—combined with increasingly sedentary lifestyles and unhealthy dietary habits, is fueling demand for effective and safe weight management solutions. As healthcare providers and consumers alike place greater emphasis on preventive care and long-term wellness, the weight loss drugs market is experiencing substantial growth, driven by medical innovation, regulatory support, and a strong focus on improving patient outcomes.
Weight Loss Drugs Market- Market Dynamics
Increasing Awareness of Health Risks Linked to Obesity
With the rise of public health campaigns, increased media coverage, and ongoing medical research highlighting the serious health risks associated with obesity—such as type 2 diabetes, heart disease, certain cancers, and respiratory issues—more people are recognizing the importance of effective weight management. According to the World Health Organization (WHO), the global rate of obesity has nearly tripled since 1975. As of 2023, over 1.9 billion adults were classified as overweight, with more than 650 million considered obese. This growing awareness is driving individuals to seek effective treatment options, including weight loss medications, to mitigate these health risks. In response, healthcare providers are increasingly recommending pharmacological treatments alongside lifestyle interventions. As a result, global demand for weight loss drugs is surging, prompting pharmaceutical companies to develop safer and more effective solutions to address this critical health issue.
For Instance,
- In January 2024, Novo Nordisk expanded the international availability of its flagship weight loss drug, Wegovy (semaglutide). This strategic move aims to meet the rising global demand for obesity treatments and further solidifies Novo Nordisk’s leadership in the weight management sector, helping more patients around the world combat obesity and its associated health risks.
Weight Loss Drugs Market- Key Insights
- According to analysis conducted by our research team, the global weight loss drugs market is projected to grow at a compound annual growth rate (CAGR) of approximately 19.29% during the forecast period from 2025 to 2032.
- By type, prescription drugs accounted for the largest market share in 2024.
- In terms of dosage form, injections emerged as the dominant segment in 2024.
- Based on application, appetite suppression led the market in 2024.
- Regarding distribution channels, retail pharmacies held the largest share in 2024.
- Regionally, North America was the top revenue-generating market in 2024.
Weight Loss Drugs Market- Segmentation Analysis:
The global weight loss drugs market is segmented on the basis of type, dosage form, application, distribution channel, and region.
The global weight loss drugs market is segmented by type into over-the-counter (OTC) drugs and prescription drugs, with the prescription drugs segment currently dominating the market. This dominance is primarily attributed to the clinical effectiveness and safety profile of prescription medications, which are typically used under medical supervision to manage moderate to severe obesity. These drugs often involve advanced formulations that specifically target metabolic pathways, suppress appetite, or inhibit fat absorption, making them more reliable for long-term weight management. Physicians prefer prescribing these medications because they deliver clinically validated outcomes and are subject to rigorous regulatory approvals. Moreover, the increasing global burden of obesity-related complications—such as type 2 diabetes, cardiovascular diseases, and hypertension—is contributing to a higher rate of physician-recommended prescription treatments. According to the World Health Organization (WHO), global obesity rates have nearly tripled since 1975, and in 2022, more than 1 billion people worldwide were classified as overweight or obese, emphasizing the growing need for medically supervised and effective pharmacological interventions.
Based on application, the weight loss drugs market is categorized into appetite suppression, fat blocking, and others, with the appetite suppression segment holding the largest share. Appetite suppressants function by targeting the central nervous system to reduce hunger signals and control cravings, thereby helping individuals lower calorie intake and maintain consistent weight loss over time. This direct and behavioral-focused mechanism makes them a preferred option for both healthcare professionals and patients seeking long-term obesity management. Additionally, recent innovations in drug formulations have led to improved safety, efficacy, and tolerability, enhancing patient adherence and satisfaction. As obesity continues to rise globally—especially in urbanized and sedentary populations—appetite suppressants remain a cornerstone of pharmacological weight management. According to the World Obesity Federation, it is projected that by 2035, over 50% of the global population could be overweight or obese if current trends persist, underscoring the urgent need for effective and scalable solutions like appetite suppressants to combat this public health crisis.
Weight Loss Drugs Market- Geographical Insights
North America is expected to dominate the global weight loss drugs market throughout the forecast period, maintaining its leading position in 2024.
North America currently dominates the global weight loss drugs market, holding the largest market share due to its high obesity prevalence, well-developed healthcare infrastructure, and broad access to advanced pharmaceutical treatments. The United States leads the region, with a substantial portion of the adult population classified as overweight or obese. The early regulatory approval and commercial success of weight loss drugs such as Wegovy (Novo Nordisk) and Zepbound (Eli Lilly) have significantly accelerated market growth. In addition, favorable reimbursement policies, increasing public awareness of obesity-related health risks, and active government initiatives aimed at combating obesity further reinforce North America\'s market leadership. According to the Centers for Disease Control and Prevention (CDC), over 42% of U.S. adults were classified as obese in 2020—a number that continues to rise—underscoring the ongoing need for effective weight management solutions in the region.
The Asia Pacific region is projected to record the highest compound annual growth rate (CAGR) in the weight loss drugs market during the forecast period, starting in 2024.
In contrast, the Asia-Pacific region is emerging as the fastest-growing market for weight loss drugs, driven by rapid urbanization, sedentary lifestyles, and changing dietary habits, which have led to a sharp increase in obesity rates. Countries such as China, India, and South Korea are witnessing a surge in obesity-related health conditions, including type 2 diabetes and cardiovascular diseases. This trend, coupled with rising disposable incomes, improved access to healthcare services, and growing acceptance of pharmaceutical solutions for weight management, is propelling demand across the region. Additionally, government-backed health initiatives and public awareness campaigns focused on obesity prevention are further supporting market expansion. According to the World Health Organization (WHO), the prevalence of overweight and obesity in Asia is increasing rapidly, with projections indicating that over 1 billion people in the Asia-Pacific region could be overweight or obese by 2030, highlighting the urgent need for effective therapeutic interventions.
Weight Loss Drugs Market- Competitive Landscape:
The global weight loss drugs market is highly competitive and rapidly evolving, driven by a combination of pharmaceutical giants, emerging biotech firms, and increasing investments in research and development focused on obesity treatment. Key industry leaders such as Novo Nordisk, Eli Lilly, Pfizer, Johnson & Johnson, and GlaxoSmithKline (GSK) are actively competing through product innovation, advanced clinical trials, and global market expansion strategies. Novo Nordisk currently holds a dominant market position, largely due to the success of its flagship weight loss medication Wegovy (semaglutide), which has shown strong clinical outcomes and continues to see growing global demand. Meanwhile, Eli Lilly has quickly emerged as a strong competitor with Zepbound (tirzepatide)—a dual-action treatment effective for both type 2 diabetes and weight loss. To meet increasing demand, both companies are expanding manufacturing capacities and entering new international markets.
Other major players like Pfizer and GSK are focusing on strategic partnerships and R&D pipelines to strengthen their positions in this fast-growing sector. At the same time, smaller biotech firms are entering the scene with novel obesity treatments and innovative mechanisms of action, adding further dynamism to the market. The competitive landscape is increasingly defined by advancements in drug efficacy, safety profiles, dosing convenience, and long-term outcomes. Companies are also pursuing collaborations, licensing agreements, and acquisitions to enhance their market reach. As global obesity rates continue to rise, competition in the weight loss drug market is expected to intensify, driving continuous innovation and strategic activity.
Recent Developments:
- June 2025 – Eli Lilly announced a strategic partnership with Amazon Pharmacy to distribute its weight loss drug Zepbound (tirzepatide) directly to consumers. The initiative aims to enhance patient access and convenience while expanding Eli Lilly’s presence in digital health and obesity care.
- April 2025 – Novo Nordisk acquired Emisphere Technologies, a company specializing in oral drug delivery systems. This acquisition is expected to support the development of oral formulations of semaglutide, improving patient compliance and expanding accessibility, while reinforcing Novo Nordisk’s leadership in both injectable and oral weight loss therapies.
- January 2025 – Johnson & Johnson entered a co-development partnership with a U.S.-based biotech firm to create dual-acting metabolic modulators for obesity management. The collaboration aims to develop next-generation treatments that offer safer and more sustainable weight loss solutions, highlighting J&J’s renewed commitment to combating obesity and related metabolic disorders.
- October 2024 – GlaxoSmithKline (GSK) launched Phase 2 clinical trials for a novel appetite suppressant targeting central nervous system pathways. This initiative is part of GSK’s strategy to expand its metabolic health portfolio with innovative, first-in-class treatments designed to deliver high efficacy, better patient compliance, and minimal side effects.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL WEIGHT LOSS DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Eli Lilly and Company
- Amgen Inc.
- AstraZeneca
- F. Hoffmann-La Roche Ltd (Roche Holding AG)
- GlaxoSmithKline plc
- Ionis Pharmaceuticals, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Rhythm Pharmaceuticals, Inc.
- Sanofi S.A.
- Structure Therapeutics Inc.
- Takeda Pharmaceutical Company Limited
- VIVUS, Inc.
- Zafgen, Inc.
- Eisai Co., Ltd.
- Boehringer Ingelheim International GmbH
- Currax Pharmaceuticals LLC
- Others
GLOBAL WEIGHT LOSS DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032
- Over-the-counter drugs (OTC)
- Prescription Drugs
GLOBAL WEIGHT LOSS DRUGS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032
- Capsules
- Injections
- Liquids
- Tablets
GLOBAL WEIGHT LOSS DRUGS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- Appetite Suppression
- Fat Blocking
- Others
GLOBAL WEIGHT LOSS DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Online Pharmacy
- Hospital Pharmacy
- Retail Pharmacy
GLOBAL WEIGHT LOSS DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Weight Loss Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Weight Loss Drugs Market Snippet by Type
2.1.2. Weight Loss Drugs Market Snippet by Dosage Form
2.1.3. Weight Loss Drugs Market Snippet by Application
2.1.4. Weight Loss Drugs Market Snippet by Distribution Channel
2.1.5. Weight Loss Drugs Market Snippet by Country
2.1.6. Weight Loss Drugs Market Snippet by Region
2.2. Competitive Insights
3. Weight Loss Drugs Key Market Trends
3.1. Weight Loss Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Weight Loss Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Weight Loss Drugs Market Opportunities
3.4. Weight Loss Drugs Market Future Trends
4. Weight Loss Drugs Industry Study
4.1. PESTEL Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Weight Loss Drugs Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Weight Loss Drugs Market Landscape
6.1. Weight Loss Drugs Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Weight Loss Drugs Market – By Type
7.1. Overview
7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
7.1.2. Over-the-counter drugs (OTC)
7.1.3. Prescription Drugs
8. Weight Loss Drugs Market – By Dosage Form
8.1. Overview
8.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
8.1.2. Capsules
8.1.3. Injections
8.1.4. Liquids
8.1.5. Tablets
9. Weight Loss Drugs Market – By Application
9.1. Overview
9.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
9.1.2. Appetite Suppression
9.1.3. Fat Blocking
9.1.4. Others
10. Weight Loss Drugs Market – By Distribution Channel
10.1. Overview
10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
10.1.2. Online Pharmacy
10.1.3. Hospital Pharmacy
10.1.4. Retail Pharmacy
11. Weight Loss Drugs Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Weight Loss Drugs Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Weight Loss Drugs Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Weight Loss Drugs Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Weight Loss Drugs Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Weight Loss Drugs Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Weight Loss Drugs Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Eli Lilly and Company
12.2.2. Amgen Inc.
12.2.3. AstraZeneca
12.2.4. F. Hoffmann-La Roche Ltd (Roche Holding AG)
12.2.5. GlaxoSmithKline plc
12.2.6. Ionis Pharmaceuticals, Inc.
12.2.7. Johnson & Johnson
12.2.8. Merck & Co., Inc.
12.2.9. Novartis AG
12.2.10. Teva Pharmaceutical Industries Ltd.
12.2.11. Pfizer Inc.
12.2.12. Rhythm Pharmaceuticals, Inc.
12.2.13. Sanofi S.A.
12.2.14. Structure Therapeutics Inc.
12.2.15. Takeda Pharmaceutical Company Limited
12.2.16. VIVUS, Inc.
12.2.17. Zafgen, Inc.
12.2.18. Eisai Co., Ltd.
12.2.19. Boehringer Ingelheim International GmbH
12.2.20. Currax Pharmaceuticals LLC
12.2.21. Others
13. 360 Degree Analyst View
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
